Phase 3 Study of Vfend & Eraxis Combo Therapy for Invasive Aspergillosis

Pfizer announced results from its Phase 3 study comparing combination therapy of Vfend (voriconazole; Pfizer) and Eraxis (anidulafungin; Pfizer) to Vfend monotherapy for the treatment of invasive aspergillosis (IA). The primary analysis of this double-blinded, prospective, randomized, clinical trial was to compare mortality rates at six weeks after initiation of study treatment in patients with a diagnosis of proven or probable IA. Treatment with the combination of Vfend and Eraxis resulted in a lower all-cause mortality rate at six weeks compared to Vfend alone. However, this difference in mortality did not achieve the pre-specified threshold for statistical superiority. The safety and tolerability of the combination of Vfend and Eraxis in this study was similar to that of Vfend monotherapy.

Vfend IV/Oral is a broad-spectrum IV/oral triazole antifungal medication specifically indicated for the first-line treatment of both mold and yeast infections. Eraxis for Injection belongs to the echinocandin class of antifungal drugs and is used to treat serious fungal infections caused by Candida.

For more information visit www.vfend.com or visit www.eraxisrx.com.